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The iterative application of a large chemical space  
in the drug discovery process
Abstract
Aim. To demonstrate the advantages of large-scale virtual libraries generated using chemical protocols previously validated 
in primary steps of the drug discovery process.
Results and discussion. Two validated parallel chemistry protocols reported earlier were used to create the chemical space. 
It was then sampled based on diversity metric, and the sample was subjected to the virtual screening on BRD4 target. Hits of 
virtual screening were synthesized and tested in the thermal shift assay.
Experimental part. The chemical space was generated using commercially available building blocks and synthetic proto-
cols suitable for parallel chemistry and previously reported. After narrowing it down, using MedChem filters, the resulting 
sub-space was clustered based on diversity metrics. Centroids of the clusters were put to the virtual screening against the BRD4 
active center. 29 Hits from the docking were synthesized and subjected to the thermal shift assay with BRD4, and 2 com-
pounds showed noticeable dTm.
Conclusions. A combination of cheminformatics and molecular docking was applied to find novel potential binders for BRD4 
from a large chemical space. The selected set of predicted molecules was synthesized with a 72 % success rate and tested in 
a thermal shift assay to reveal a 6 % hit rate. The selection can be performed iteratively to fast support of the drug discovery.
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Ітеративне використання великих хімічних просторів у пошуку лікарських засобів
Анотація 
Мета. Продемонструвати переваги віртуальних бібліотек великого розміру, згенерованих за валідованими раніше 
хімічними протоколами, на перших етапах пошуку лікарських засобів.
Результати та їх обговорення. На основі двох валідованих методів синтезу, придатних для паралельної хімії, описа-
них раніше, було створено хімічний простір. На основі різноманітності з одержаної віртуальної бібліотеки зроблено 
вибірку, яку було піддано віртуальному скринінгу щодо активного центру білка BRD4. Хіти віртуального скринінгу було 
синтезовано й перевірено за допомогою диференційної сканувальної калориметрії.
Експериментальна частина. На основі комерційно доступних вихідних реагентів та раніше репрезентованих синте-
тичних протоколів, придатних для паралельної хімії, згенеровано хімічний простір. Простір було зменшено за раху-
нок застосування медхімічних фільтрів; результатний підпростір було кластеризовано за критерієм різноманітності. 
Центроїди кластерів було піддано молекулярному докінгу щодо активного центру білка BRD4. За результатами прове-
деного докінгу, синтезовано 29 хітів, які було піддано диференційній сканувальній калориметрії з білком BRD4; з цим 
2 сполуки продемонстрували помітний зсув точки топлення.
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Висновки. Для пошуку нових потенційних лігандів BRD4 у великому хімічному просторі було застосовано комбінацію 
хемоінформатики і молекулярного докінгу. Набір молекул, що мали високу передбачену активність, було синтезова-
но з успішністю 72 %. Серед синтезованих сполук виявлено первинні хіти (6 % сполук). Подібний процес можна по-
вторювати ітеративно для швидкої підтримки розроблення ліків.
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■ Introduction
A high throughput screening (HTS) has been 
a tool for medicinal chemists for decades [1, 2]. These 
days, however, direct use of HTS at the first sta- 
ges of the drug discovery rarely happens. The draw-
backs of this method are its cost and limited ran- 
ge of compounds available in stock – and no solid 
guarantees are given that the experiment yields 
potent compounds.
To substantially decrease the required expe- 
rimental costs, the virtual screening, including mo-
lecular modeling, molecular docking, and AI/ML- 
based (Artificial Intelligence/Machine learning) 
approaches have been widely introduced and suc-
cessfully utilized [3 – 5]. The latter allows screening 
in-stock and virtual compounds resulting in mo- 
lecules with favorable profiles, which can be eva- 
luated before involving the experimental part. 
Many approaches exist to generate a virtual lib- 
rary [6]. But the major point is that the compounds 
should be synthetically feasible to enable the expe- 
rimental screen. Introduced by Enamine Ltd. 
concept of the REAL (REadily AccessibLe) com-
pounds has shown its applicability to generate 
a multi-billion chemical space (the REAL space) 
of synthesizable compounds [7]. The REAL com-
pounds are accessible via in-house validated one-pot 
parallel chemistry applied to in-house available 
building blocks and reagents [8, 9]. The variety of 
the synthetic transformations and involvement 
of a large pool of the reagents allow building di-
verse libraries introducing new chemotypes for 
various targets [10, 11].
Validated parallel chemistry protocols result 
in an enormous expansion of virtual databases 
[12] and may create a cost-to-screen issue, simi-
lar to the one for HTS. Indeed, molecular docking of 
one million structures is performed on a modern 
personal computer, but the virtual screening of 
one billion structures requires a powerful cluster 
or a cloud. Many small or medium-sized compa-
nies and research groups lack access to the above 
resources. Also, large libraries utilize substantial 
storage: one million molecules represented as 1,000 
conformers per structure to better probe the space 
(i.e., 1,000,000,000 conformers in total) require 
a few terabytes of storage.
Nevertheless, molecular docking of large virtual 
libraries is impossible [11]. Many approaches exist 
to utilize fewer resources by sampling a chemi-
cal space before the screen [13]. In this work, we 
study a part of the REAL space built utilizing 
two transformations [8, 14] applying sampling 
to the output to get a representative small dock-
able set of compounds. We further demonstrate 
the advantages of having virtual libraries of syn-
thesizable compounds in the primary hit identi-
fication showing the speed and efficacy of such 
an approach to support fast turnaround. We ap-
ply our approach to identify selective binders of 
BRD4, a member of the bromo- and extra termi- 
nal domain protein family associated with can-
cer, cardiovascular diseases, inflammation pro-
cesses, CNS disorders [15 – 17].
■ Results and discussion
Chemical space
Over the last two years, we proposed two ap-
proaches to deliver multimillion chemical libra- 
ries based on heterocyclic scaffold-like cores [8, 14]. 
The chemical space generated based on the ap-
proaches meets the REAL paradigm: 
1) a wide range of starting reagents is avail-
able, amines and carboxylic acids, both classes 
contribute greatly to the universe of the commer-
cially available building blocks and reagents;
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2) one-pot procedures are compatible with 
the parallel chemistry setup;
3) the optimization of synthetic procedures af-
fords medium to high synthesis success rates. 
A heterocyclic central core acts as a rigid linker. 
The molecules in the library extend in two or three 
directions in the case of tetrazole- or triazole-ba- 
sed structures, respectively (Figure 1).
For this study, we generated a virtual libra- 
ry of the REAL compounds from these two reactions 
and commercially available in-stock reagents. 
We focused on the drug-like space limited by Veber 
rules [18, 19], which resulted in 221,000,000 indi-
vidual REAL molecules (physicochemical profiles 
and the quality assessment of the library are given 
in the Supporting Information File). The samp- 
ling of the library by grouping resulted in reduc-
tion to 100,000 clusters. The centroids of the clus-
ters were further utilized in virtual screens against 
BRD4.
Target preparation and molecular docking
For target preparation, we reviewed informa-
tion from UniProt [20], ChEMBL [21], and Protein 
Data Bank [22] for all known BRD4(1) protein-
ligand complexes. After a thorough analysis of 
the available structures we selected 3U5L(08K) 
[23] complex to model the 3D structure of the ac- 
tive center (Figure 2).
The binding mode of the ligand in 3U5L(08K) 
is characterized by a lipophilic sandwich of its fu- 
sed core between residues Val87, Leu92, Leu94, 
and Tyr97 from one side, and Phe83 and Ile146 
from the other side of the binding pocket (Figure 2). 
The van der Waals interaction energy in this host- 
guest pair is dominant. This observation positi- 
vely correlates with the molecular size; hence, 
a higher false-positive rate by the scoring func-
tion can be expected for larger compounds. To ad-
dress this issue, we manually inspected the ulti-
mate set of top-scoring molecules received after 
the virtual screen. The key electrostatic interac-
tion is a hydrogen bond between the benzotriaze- 
pine moiety of the ligand with the highly con-
served Asn140, a typical feature among bromo-
domain inhibitors as acetyl-lysine mimics. Water 
molecules found at the bottom of the pocket are non- 
displaceable in all known structures. Compound 
08K also occupies the hydrophobic sub-pocket lo-
cated in between Trp81, Pro82, Met149, and Ile146 
residues, an important region for the ligand de-
sign to gain potency. 
Additional justification for a protein-ligand 
complex was from the analysis of multiple mole- 
cular dynamics (MD) simulations of 55 compounds 
with different anchor fragments starting from their 
docked poses into BRD4(1). The study allowed 
us to evaluate the main binding interactions, 







Figure 1. A potential molecule expansion for the REAL 
tetrazoles (1) and the REAL triazoles (2)
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for example, the stability of the hydrogen bond 
with Asn140 [24]. The MD simulations revealed 
that the binding modes of some of the chemoty- 
pes selected were not stable. Ligands are known 
to induce differences in shape among crystal struc-
tures and this, in turn, changes the structure and 
binding energy predictions of any docking protocol. 
To increase the chances of successful identification 
of new diverse chemotypes for BRD4(1), we used 
the X-ray crystal structure model with a co-crys-
tallized ligand 08K. This protein-ligand complex 
resembles all characteristic features of BRD4(1) 
and was experimentally resolved (PDB: 3u5l) [23].
There are a few observations that should be 
attention paid to:
•	 Asn140	acts	as	a	key	residue
As previously discussed [24, 25], there are con-
served interactions within the BRD4(1) binding site. 
Comparison of the crystal structure of BRD4(1) 
(3U5L) in a complex with a benzotriazepine-like 
ligand (08K) to any of the known BRD4 protein-
ligand complexes reveals the same conserved in-
teractions between the protein and the bound 
ligand. Figure 2 shows this contact as an orange 
solid line (2.16Å) representing a hydrogen bonding 
interaction with the NH2-group (Asn140), while 
the residues are shown as sticks.
•	 A	key	water	molecule	at	Tyr97
One water molecule (HOH219, at 2.059Å from 
the nitrogen of 08K) is conserved across most of 
the chemotypes known. It plays an important role 
by bridging between the ligand and the Tyr97 
residue through hydrogen bonds. This water mole-
cule is in the chain of 8 commonly conserved wa-
ter molecules and is the closest water to Asn140.
•	 A	cascade	of	8	water	molecules	retaining	ac-	
ross	the	known	X-ray	structures	of	BRD4(1)
There are conserved water interactions across 
various known X-ray structures. Especially, eight 
water molecules are retained in most BRD4(1) 
structures. It appears to be unlikely to alternate 
such an ensemble of interconnected water mole- 
cules with a ligand fragment. Therefore, these 
water molecules (Figures 3 and 4) were preser- 
ved in our simulations. Elimination of all other 
water molecules allowed to study new interactions.
•	 A	hydrophobic	sub-pocket	with	a	prefer-
able	�-�	interaction
As observed previously, an important feature 
of the potentially active molecules along with 
the binding to Asn140 would be an occupation of 
the sub-pocket S2 being close to Trp81, Pro82, 
Met149, and Ile146 residues (Figure 3). 
The molecular docking study and subsequent 
selection of top-scoring molecules have identified 
40 potential BRD4(1) binders. One of the mole-
cules is shown in Figure 3. Compound 1{32,31,15} 
is remarkably well accommodating the main po- 
cket S1 with a propyl group terminated with 
a triazole ring, while the central triazole moiety 
occupies an important sub-pocket S2. Further-
more, the other part of 1{32,31,15} gains some 
extra energy from a T-shape �-� contact with 
Trp81.
Figure 3. A docking pose of the ligand 1{32,31,15} in BRD4(1). The molecule of the ligand has been partially truncated  
for better representation and clarity
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Another molecule from the set, 1{13,13,6}, in-
teracts with the active site by engaging its car-
bonyl group into hydrogen bonding interactions 
with (a) the key residue Asn140 and with (b) 
a water molecule bridging over to Tyr97. These 
interactions are sufficient to keep the molecule in 
the pocket and leave the sub-pocket S2 vacant.
Chemical synthesis and thermal shift 
assay
All top-scoring molecules were selected for 
the synthesis. The synthesis performed as descri- 
bed [8, 14] resulted in 29 compounds (72.5 % suc-
cess rate). The list of the compounds obtained 
with docking scores is given in the Supporting 
Information File.
All the compounds synthesized were screened 
against BRD4(1) in the thermal shift assay (the de-
tailed information is given in the Experimental 
part). Two compounds, 1{13,13,6} and 1{32,31,15} 
(Table), showed a noticeable shift (Figure 5).
A counter screen experiment against the non-
related proteins (SIRT1 and Abl SH2) confirmed 
Figure 4. A docking pose of the ligand 1{13,13,6} in BRD4(1). The molecule has been partially truncated for better  
representation and clarity
 
Table. Hit molecules after a single round of the screening
Structure Identifier Docking score
Distance to the nearest 




1{13,13,6} -41.58 0.72 [26] 0.76
1{32,31,15} -40.04 0.82 [27] 0.75
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the selectivity of the above hits towards BRD4 
showing no significant influence on the stability 
of the latter proteins. Therefore, the hit rate for 
the screen was 6 %.
Hit expansion from the generated che- 
mical space
One of the advantages of our approach is that 
the analogs for hit expansion for the hits tested 
are readily accessible from the very same chemical 
space the hits were selected from. For 1{13,13,6}, 
there are 185 ready-for-synthesis compounds 
with a Tanimoto similarity over 0.65 (MFP2). 
For 1{32,31,15}, we have found over 140 analogs 
by the same metric. The analogs are available 
for a wet screening within 3 – 4 weeks. 
Discussion
The drug discovery is an expensive process, 
and speeding up its stages is very important [28]. 
The approach proposed will allow finding hit mole-
cules from a large dense chemical space (Figure 6). 
The creation of the space according to the cri-
teria described gives an access to high-quali-
ty molecules (Step 1). Wise sampling supports 
the diversity of chemotypes and full coverage 
of the space (Step 2). The sampled subset is scre- 
ened faster and more economically compared with 
the full space (Step 3). The synthesis of the mo- 
lecules selected results in more than 70 % of com- 
pounds delivered for a wet assay within 3 – 4 weeks 
(Step 4). Once found the hit series can be expan- 
ded with 1,000 – 10,000 make-on-demand ana-
logs available for a wet screening in 3 – 4 weeks 
(Steps 5 – 8). The latter steps can be iterated to 
find more potent analogs compared with the ini-
tial hits. If successful, the approach will allow 
speeding up the hit-to-lead or even lead optimi-
zation stages.
■ Conclusions
We evaluated a methodology for obtaining 
starting points at the initial stages of the drug 
discovery. The approach proposed is suitable for 
a rapid (6 – 8 weeks) hit expansion from a dense 
chemical space. When iterated the approach can 
be applied to the hit to lead stage speeding it up 
by the application of the fast synthesis and hit 
evaluation steps.
Figure 5. Values of median dTm for the screened compounds against BRD4 (Orange); Abl SH2 (Blue), and SIRT1 (Green)
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■ Experimental part
Chemical space generation, cutoffs, clu- 
stering
The chemical space was generated from the in-
stock available building blocks using reactions 
of the formation of aminotetrazoles and amino-
triazoles [8, 14]. The whole chemical space com-
prised 674 million unique compounds.
Narrowing down the space by utilizing “Drug- 
Likeness” and “Veber Rules” criteria [19, 30], as well 
as using substructure filters (e.g., PAINS as imple-
mented in RDKit) [31] resulted in 221 million 
compounds. This subset of molecules was further 
diversified utilizing Morgan Fingerprints (MFP2) 
in conjunction with Tanimoto Similarity metrics. 
For this purpose, the following functions imple-
mented in the RDKit package for python were 
used: LazyBitVectorPick() from rdkit.SimDivFil- 
ters.MaxMinPicker().
Ultimately, a diverse subset of a hundred 
thousand dissimilar molecules was subjected to 
the molecular docking study.
Docking
In our virtual screens, we have used Dock [32]. 
Reference active ligands, decoys, and the diver-
sified set of triazole/tetrazole derivatives were 
docked into the BRD4 binding site of the 3U5L 
protein structure using DOCK 3.7.3 [33].
The docking program places pre-generated 
flexible ligands into the binding site (specified by 
matching spheres) via atomic superposition of 
each prob molecule on matching spheres (genera- 
ted based on the crystallographic ligand), thus, 
representing favorable atomic positions of each 
conformer prior to scoring. The general pipeline 
for placing matching spheres into the binding site 
is to use the crystallographic ligand heavy atoms 
as the first set of spheres and then to add nearby 
spheres generated by SPHGEN routine until a set 
number of matching spheres is reached. By de-
fault, forty-five matching spheres were used in 
the template receptor structure. The resulting 
ligand poses were scored by adding up the recep-
tor-ligand electrostatic interaction energies to van 
der Waals interaction energies, and then correc- 
ted for context-dependent ligand desolvation. 
The receptor structure was protonated using 
a Reduce program [34]. Partial charges from the uni- 
ted-atom AMBER [35] force field were used for all re-
ceptor atoms. The grid to evaluate protein-ligand 
electrostatics was pre-calculated using a QNIFFT 
[36, 37] program. CHEMGRID[38] was used to 
make the van der Waals grid using an AMBER 
forcefield for the receptor. SOLVMAP [39] was 
used to calculate a grid for the evaluation of the 
ligand desolvation term.
Synthesis
Experimental procedures applied for the synthe-
sis of compounds were described [8, 14]. The syn-
thesis was completed in 3 weeks, with 29 of 40 se- 
lected compounds synthesized and 72.5 % suc-
cess rate.
Assays 
All thermal shift assay (TSA) experiments with 
BRD4 protein were performed using a ViiA™7 
real-time PCR System equipped with a 384-well heat 
block (Applied Biosystems, Waltham, MA, USA). 
The optimal buffer composition for the TSA proce-
dure was determined as described previously [40]. 
The buffer consisting of 50 mM Phosphate-Na, 
100 mM NaCl, pH 7.5 was selected for the BRD4 
screening in the previous study [41]. A purified 
BRD4 protein was pre-mixed with SYPRO Orange 
dye (Thermo Fischer Scientific, Cat. S6650, 5000x 
stock, Waltham, MA, USA) to prepare a master 
mix in the concentrations of 4 µM protein and 
6× dye. The compounds tested were added to the pro-
tein- at 40 µM in the final DMSO concentration 
of 2 % and pre-incubated at room temperature 
Figure 6. General workflow
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for 15 min in MicroAmp® optical 384-well reac-
tion plates (ThermoFisher, Cat. 4309849, Walt- 
ham, MA, USA) sealed with an optical sealing film 
(ThermalSeal RT2, Excel Scientific, Cat. TS-RT2, 
Victorville, CA, USA). After the compounds pre-
incubation with the protein the dye was added 
to all wells making the final concentration of 6×. 
The volumes of all reaction mixtures were 10 µL 
(4 µg BRD4 per well). The thermal scanning was 
performed by raising the temperature to 40 °C 
at 1.6 °C/min without the signal detection followed 
by 40 °C to 90 °C temperature ramp at 0.05 °C/s 
with the constant fluorescence intensity reading 
at 2-sec intervals using an EX470/EM623 nm fil-
ter set.
Assay procedures for SIRT1 and Abl SH2 were 
the same as for BRD4, with exception of the assay 
buffer composition, protein, and dye concentra-
tion, which were used. Additionally, the thermal 
ramp was adopted individually for each protein.
While testing the compounds with SIRT1 the re-
action was kept in the following assay buffer: 20 mM 
Tris pH 7.5 and 50 mM NaCl. The protein and dye 
were added to the final concentration of 1.3 µM 
and 8×, respectively. The thermal scanning was 
performed by raising the temperature to 35 °C 
at 1.6 °C/min without the signal detection followed 
by 35 °C to 75 °C temperature ramp at 0.05 °C/s 
with the constant fluorescence intensity reading
at 2-sec intervals using an EX470/EM623 nm 
filter set.
During the assessment of compounds with 
Abl SH2 the reaction was kept in the following 
assay buffer: 50 mM Tris, 150 mM NaCl, and 2 mM 
MgCl2. The protein and dye concentrations were 
1 µM and 8×, respectively. The thermal scanning 
was performed by raising the temperature to 40 °C 
at 1.6 °C/min without the signal detection followed 
by 40 °C to 75 °C temperature ramp at 0.05 °C/s 
with the constant fluorescence intensity reading 
at 2-sec intervals using an EX470/EM623 nm 
filter set.
The peak of the first derivative for the fluores-
cence curve was used to determine the melting 
temperature (Tm). The averaged Tm values for 
the control wells (64 wells per plate) containing 
only the protein, dye, and DMSO (1 %) were used 
as a reference point to determine the melting tem-
perature shifts (ΔTm). 
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